C-J Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

C-J Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-50	Closed	-$4K	–	47
2019 Q3	$4K	Hold	50	–	–	﹤0.01%	151
2019 Q2	$4K	Hold	50	–	–	﹤0.01%	153
2019 Q1	$5K	Hold	50	–	–	﹤0.01%	160
2018 Q4	$4K	Hold	50	–	–	﹤0.01%	133
2018 Q3	$4K	Hold	50	–	–	﹤0.01%	149
2018 Q2	$5K	Buy	+50	New	+$4.96K	﹤0.01%	138

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

C-J Advisory's ALNY Position: Q4 2019 in Review

C-J Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2019, closing a stake of 50 shares — an estimated $4K sold.

C-J Advisory first reported a position in ALNY in Q2 2018 and held it in 6 quarters. The position peaked at $5K in Q1 2019. 316 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

C-J Advisory reported no remaining Alnylam Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
C-J Advisory sold 50 Alnylam Pharmaceuticals shares in Q4 2019, an estimated $4K.
C-J Advisory first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 6 quarters.
C-J Advisory's Alnylam Pharmaceuticals position peaked at $5K in Q1 2019.
316 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on C-J Advisory's 13F filing for Q4 2019, filed 10 Feb 2020.